Ventrus Biosciences Inc. (VTUS -9.8%) slides after getting FDA feedback requiring a second Phase...

|By:, SA News Editor

Ventrus Biosciences Inc. (VTUS -9.8%) slides after getting FDA feedback requiring a second Phase 3 study of its diltiazem hydrochloride cream - a treatment for anal fissures - before any new drug application can be filed. The drug developer says it expects to file the NDA following completion of the second Phase 3 study, with results expected early Q4 2013, and expects to file an NDA late in Q4 2013 with an anticipated PDUFA date near the end of 2014.